Could a common antibiotic replace stronger ones for severe pneumonia?
NCT ID NCT07322549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 104 adults in the ICU with severe pneumonia caused by three common bacteria. Researchers checked whether the bacteria were sensitive to amoxicillin/clavulanic acid (AMC) or to third-generation cephalosporins (3GC), which are standard treatments. The goal was to see if AMC could be a good alternative to help reduce antibiotic resistance. The study only reviewed past medical records, so it cannot prove which treatment is better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amoxicillin/clavulanic acid (AMC) and third-generation cephalosporins (3GC)
What this could lead to
If the results show AMC works well, it could offer a narrower-spectrum antibiotic option for severe pneumonia, potentially reducing antibiotic resistance.
What could go wrong
This is a small, single-center retrospective study, not a controlled trial. It only looks at past data, so it cannot prove which antibiotic is better. Results may not apply to other hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE COMMUNITY-ACQUIRED PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
Toulon, Var, 83100, France